Live · Pharma Commercial Intelligence · by MoatRx

Intelligence you can put in front of a payer.

Every figure in an AXLRx brief — competitive, patient, and payer — is verified against a live source as it is written. If it can't be sourced, it doesn't ship. Delivered in 72 hours.

0h
Scope → delivery
0%
Live-sourced
0
Unsourced figures
AXLRx Intelligence Console · NSCLC / US BUILDING · VERIFYING
Briefassembling
✓ VERIFIED
Oncology · Competitive Intelligence
NSCLC — Pre-Launch, US
BRIEF 01 · 30 PP · 8 SECTIONS
FIG. 03 Competitive map
AgentmOSShare
Pembrolizumab26.352%
Nivo + Ipi15.618%
Your assetEx.7
FIG. 02 Patient funnel
Diagnosed100
IO-eligible~60
Your cohort~22
Source ledgerlive
IncidenceSEER 2024
mOS 26.3PMID 27718847
mOS 15.6PMID 34126067
Share 41%no source
PFS 16.9PMID 28885881
Coveragepayer URL
PD-L1 ≥50%FDA label
6 VERIFIED · 1 DROPPED100% SOURCED
§01 · Coverage

One console, built for four commercial stages.

Every brand decision sits in one of four stages — each answering a single buyer question, each scoped to your asset. The brief types live inside them.

§02 · The work

What a brief actually contains.

Not prose about the market — built exhibits a commercial team can decide on. Three from a typical brief, every figure sourced.

FIG. A — Competitive map
Who holds which cohort, on what evidence.
AgentPD-L1mOSShare
Pembrolizumab≥50%26.352%
Nivo + IpiAny15.618%
DurvalumabAny47.512%
Your assetTBDEx.7
SRC ↗ PMID 27718847 · 34126067 · 28885881
FIG. B — Patient funnel
The addressable pool, built bottom-up.
Diagnosed100
Systemic-eligible~78
IO-eligible~60
Your cohort~22
Indexed to 100 diagnosed · illustrative
FIG. C — Capture scenarios
Year-3 share, by cohort not in aggregate.
4%Conservative — late access, full competitive response
9%Base — on-label timing, parity evidence
15%Aggressive — first-in-cohort differentiation
Y3 share, IO-eligible cohort · sensitivity in model
§03 · The standard

The ledger above is not a demo — it is the discipline.

Commercial intelligence is where AI confidently reproduces outdated trials and figures that were never real. AXLRx uses none of its own memory as a source.

  • Every claim cited to a live PMID, trial ID, or URL at the point of writing — uncited claims are dropped, not estimated
  • PubMed metadata fetched live during authoring — model memory mis-attributes authors and journals even on correct identifiers
  • Numeric cross-check: the figure must appear in the cited source, not merely be consistent with it
  • An independent audit pass runs after generation — every link, claim, and number re-checked before delivery
// THE DROP GATE
mOS 26.3 mo — KEYNOTE-024 · PMID 27718847
Coverage broad — payer policy · live URL
Share 41% — no live source located
PFS 16.9 mo — PACIFIC · PMID 28885881

No confidence tiers. No "approximately." A figure that cannot clear the gate is removed.

§04 · Process

Three steps. No retainer, no six-week timeline.

STEP 01

Submit your asset

Drug, mechanism, indication, target cohort, geography — five minutes. There is no generic template; the brief is built around what you submit.

STEP 02

Confirm scope in 24h

We confirm scope, clarify the open questions, and lock the delivery window. One short call or email exchange settles it.

STEP 03

Delivered in 72h

A decision-structured PDF, an editable Excel model, and an optional executive deck — with a 30-minute readout call.

The firm behind AXLRx

The productized intelligence arm of MoatRx.

MoatRx is a pharma and life-sciences strategy and analytics consultancy. When a decision needs more than a scoped brief — a full launch strategy, a market access dossier, or sales-force design — the same team takes it on directly.

AXLRx packages that consulting rigour into fixed-scope, fast-turnaround intelligence, on the same methodology and source discipline.

Tell us your asset. Your team has the brief in 72 hours.

We build from your asset's clinical profile — mechanism, biomarker strategy, proposed label, and target cohort. Scope confirmation takes one call.

Start your request

or read a full sample brief before committing